RXi Pharmas Gene Therapy Gets Patent Boost
News Apr 20, 2016
This patent includes the Company's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the skin and eye. The patent, once issued, will not expire until 2031.
"We are pleased to have be granted this Notice of Allowance from the USPTO," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications, such as liver fibrosis".
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018